Fulgent Genetics (FLGT)
(Delayed Data from NSDQ)
$17.31 USD
-0.48 (-2.70%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $17.32 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.31 USD
-0.48 (-2.70%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $17.32 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Will FULGENT GENETIC (FLGT) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
FULGENT GENETIC (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FULGENT GENETIC Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
FULGENT GENETIC has been struggling lately, but the selling pressure may be coming to an end soon.
Fulgent Genetics (FLGT) Enters Oversold Territory
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Cyber Attack Fears Grip MedTech: 3 Safe Stocks
by Sweta Jaiswal
In the wake of rising incidences of cyber attacks in the MedTech space, we have zeroed down on some stocks which at present are safe-havens for investors.
Quality Systems Ties Up With CoverMyMeds to Enable ePA
by Zacks Equity Research
Quality Systems' (QSII) new collaboration with CoverMyMeds sees bright market prospects.
FULGENT GENETIC Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
FULGENT GENETIC has been struggling lately, but the selling pressure may be coming to an end soon.
Why FULGENT GENETICS (FLGT) Could Be Positioned for a Slump
by Zacks Equity Research
FULGENT GENETICS (FLGT) is one stock you should avoid as it has seen significant price decline and negative earnings estimate revisions.